Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 5/20 | 0.63 |
| ▸ | PPARA | Q07869 | 5/20 | 0.63 |
| ▸ | TERT | O14746 | 3/20 | 0.52 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.52 |
| ▸ | PPARD | Q03181 | 3/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | BLM | P54132 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | FABP4 | P15090 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | TOP1 | P11387 | 2/20 | 0.52 |
| ▸ | GMNN | O75496 | 1/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1375578 | 1.00 | PPARG (0.63) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL29288569 | 0.92 | PPARG (0.56) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL19900484 | 0.90 | PPARG (0.69) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL7541190 | 0.90 | PPARG (0.69) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL3264781 | 0.88 | PPARG (0.61) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL3264779 | 0.88 | PPARG (0.61) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL15216622 | 0.86 | PPARG (0.65) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL7207661 | 0.86 | PPARG (0.65) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL7207656 | 0.86 | PPARG (0.65) | PPARGPPARATERTPTPN1PPARD | |
| SCHEMBL4553754 | 0.86 | PPARG (0.65) | PPARGPPARATERTPTPN1PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11938233-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2024-03-26 | — | — | US | claimed |
| EP-4126558-A1 | VALUABLE DOCUMENT SUBSTRATE AND METHOD FOR DISINFECTION | Giesecke+Devrient Currency Technology GmbH (DE) | 2023-02-08 | — | — | EP | claimed |
| US-20220054671-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2022-02-24 | — | — | US | claimed |
| EP-3135110-B1 | 1,7-DIARYL-1,6-HEPTADIEN-3,5-DION DERIVATIVES, METHODS OF MAKING AND USING THE SAME | TRIOPTOTEC GMBH (DE) | 2019-07-10 | — | — | EP | claimed |
| US-20180272013-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | UNIVERSITÄT SALZBURG (AT) | 2018-09-27 | — | — | US | claimed |
| EP-1441697-B1 | CONDUCTANCE OF IMPROPERLY FOLDED PROTEINS THROUGH THE SECRETORY PATHWAY AND RELATED METHODS FOR TREATING DISEASE | UNIV YALE (US) | 2014-05-14 | — | — | EP | claimed |
| US-20080025921-A1 | Conductance of Improperly Folded Proteins Through the Secretory Pathway And Related Methods For Treating Disease | N-FOLD LLC | 2008-01-31 | — | — | US | claimed |
| US-20040266883-A1 | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease | YALE UNIVERSITY | 2004-12-30 | — | — | US | claimed |
| US-20030236300-A1 | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease | YALE UNIVERSITY | 2003-12-25 | — | — | US | claimed |
| US-20030149113-A1 | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease | YALE UNIVERSITY | 2003-08-07 | — | — | US | claimed |
| US-11938233-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11938233-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2024-03-26 | — | — | US | disclosed |
| US-11938233-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | UNIVERSITÄTSKLINIKUM REGENSBURG (DE) | 2024-03-26 | — | — | US | disclosed |
| US-20230310536-A1 | WATER SOLUBLE CURCUMINOIDS COMPOSITION FOR TREATING MOUTH AND THROAT CONDITIONS | MAGON ERAN (IL) | 2023-10-05 | — | — | US | disclosed |
| EP-4126558-A1 | VALUABLE DOCUMENT SUBSTRATE AND METHOD FOR DISINFECTION | Giesecke+Devrient Currency Technology GmbH (DE) | 2023-02-08 | — | — | EP | disclosed |
| US-20030149113-A1 | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease | YALE UNIVERSITY | 2003-08-07 | — | — | US | disclosed |
| WO-2003049717-A2 | CONDUCTANCE OF IMPROPERLY FOLDED PROTEINS THROUGH THE SECRETORY PATHWAY AND RELATED TREATMENTS OF DISEASES | YALE UNIVERSITY (US) | 2003-06-19 | — | — | WO | disclosed |
| EP-0861223-A1 | PROCESS FOR THE SYNTHESIS OF CURCUMIN-RELATED COMPOUNDS | Geneprint, Inc. (US) | 1998-09-02 | — | — | EP | disclosed |
| US-5679864-A | REACTING 2,4-DIKETONE WITH COMPLEXING AGENT TO PRODUCE ENOLIC REACTANT, ADDING AROMATIC ALDEHYDE, AMINE CATALYST, NEUTRALIZING | GENE PRINT INC. (US) | 1997-10-21 | — | — | US | disclosed |
| WO-1997016403-A1 | PROCESS FOR THE SYNTHESIS OF CURCUMIN-RELATED COMPOUNDS | GENEPRINT, INC. (US) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266883-A1 | Conductance of improperly folded proteins through the secretory pathway and related methods for treating disease | HSPA5, ERP44, ATP2A2 | PPARG 3261/4885PPARA 3354/4885TERT 1911/4885 |
| US-20220054671-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | DHPS, SQLE, CYP51A1 | PPARG 4052/4885PPARA 3547/4885TERT 161/4885 |
| US-20180272013-A1 | 1,7-DIARYL-1,6-HEPTADIENE-3,5-DIONE DERIVATIVES, METHODS FOR THE PRODUCTION AND USE THEREOF | DHPS, SQLE, CYP51A1 | PPARG 4052/4885PPARA 3547/4885TERT 161/4885 |
| US-11938233-B2 | 1,7-diaryl-1,6-heptadiene-3,5-dione derivatives, methods for the production and use thereof | DHPS, SQLE, CYP51A1 | PPARG 4052/4885PPARA 3547/4885TERT 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.